Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
2024年7月5日，北卡罗来纳州达勒姆 - Chimerix (纳斯达克:CMRX) 今日宣布，Chimerix 董事会补偿委员会于2024年7月1日授予两名新员工期权，购买Chimerix普通股的股票期权总数为120,000股。Chimerix董事会的补偿委员会根据纳斯达克规定5635(c)(4)规定批准了此项奖励，视此为吸引新员工就职的重要因素。
The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix's 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
这些期权的每股行使价格等于授予日期的Chimerix收盘交易价格。这些期权有10年的有效期，分四年内分配，第一年的1/4在入职一年周年时分配，其余3/4平均分配在接下来的三年内。这些期权受限于Chimerix 2024年股权激励计划的条款，但是是在其之外授予的。
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
Chimerix是一家生物制药公司，旨在开发有意义地改善和延长面对致命疾病的患者生命的药物。该公司最先进的临床阶段开发项目ONC201正在开发治疗的H3K27M突变性胶质瘤。
CONTACTS:
Will O'Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
联系方式：
威尔·奥康纳
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
Source: Chimerix, Inc.
来源：锤子医药股份有限公司。